SAM
Sectoral Asset Management Portfolio holdings
AUM
$151M
This Quarter Return
+29.39%
1 Year Return
+14.02%
3 Year Return
+79.35%
5 Year Return
+153.48%
10 Year Return
+511.68%
AUM
$1.42B
AUM Growth
+$1.42B
(+22%)
Cap. Flow
+$99.8M
Cap. Flow
% of AUM
7.03%
Top 10 Holdings %
Top 10 Hldgs %
29.29%
Holding
112
New
24
Increased
30
Reduced
36
Closed
15
Top Buys
| 1 |
Atea Pharmaceuticals
AVIR
|
$62.3M |
| 2 |
Maravai LifeSciences
MRVI
|
$27.5M |
| 3 |
Replimune Group
REPL
|
$25.5M |
| 4 |
Tandem Diabetes Care
TNDM
|
$23.8M |
| 5 |
Certara
CERT
|
$20.4M |
Top Sells
| 1 |
IMMU
Immunomedics Inc
IMMU
|
$51M |
| 2 |
HMSY
HMS Holdings Corp.
HMSY
|
$18.7M |
| 3 |
Zentalis Pharmaceuticals
ZNTL
|
$18.2M |
| 4 |
BPMC
Blueprint Medicines
BPMC
|
$17.7M |
| 5 |
Assembly Biosciences
ASMB
|
$15.1M |
Sector Composition
| 1 | Healthcare | 96.8% |
| 2 | Industrials | 1.99% |
| 3 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Guardant Health
GH
$8.11B
| $10.2M | 0.72% |
78,986
-1,400
| -2% | -$180K |
|
|
SGEN
52
DELISTED
Seagen Inc. Common Stock
SGEN
| $10.2M | 0.72% |
58,106
+3,390
| +6% | +$594K |
|
|
PSTX
53
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $9.2M | 0.65% |
838,826
-214,953
| -20% | -$2.36M |
|
54
Bristol-Myers Squibb
BMY
$96.7B
| $9.03M | 0.64% |
145,574
-52,000
| -26% | -$3.23M |
|
55
Fate Therapeutics
FATE
$115M
| $9M | 0.63% |
+99,000
| New | +$9M |
|
56
UnitedHealth
UNH
$279B
| $8.93M | 0.63% |
25,462
| – | – |
|
57
Cytosorbents Corp
CTSO
$61.5M
| $8.81M | 0.62% |
1,104,935
-525,054
| -32% | -$4.18M |
|
58
Natera
NTRA
$23B
| $8.75M | 0.62% |
+87,950
| New | +$8.75M |
|
59
Abbott
ABT
$230B
| $8.73M | 0.61% |
79,698
+6,000
| +8% | +$657K |
|
60
Eli Lilly
LLY
$661B
| $8.71M | 0.61% |
51,565
| – | – |
|
61
BioMarin Pharmaceuticals
BMRN
$11.3B
| $8.49M | 0.6% |
96,772
-54,550
| -36% | -$4.78M |
|
62
Molina Healthcare
MOH
$9.6B
| $8.08M | 0.57% |
37,972
-19,290
| -34% | -$4.1M |
|
|
CMPI
63
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
| $8.01M | 0.56% |
548,802
-51,885
| -9% | -$757K |
|
|
AVEO
64
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
| $6.64M | 0.47% |
1,151,175
+1,051,175
| +1,051% | +$6.07M |
|
65
Cigna
CI
$80.2B
| $5.78M | 0.41% |
27,741
+2,500
| +10% | +$520K |
|
66
Seer Inc
SEER
$114M
| $5.32M | 0.37% |
+94,681
| New | +$5.32M |
|
|
BLU
67
DELISTED
BELLUS Health Inc.
BLU
| $5.19M | 0.37% |
+1,696,940
| New | +$5.19M |
|
68
Amgen
AMGN
$153B
| $5.16M | 0.36% |
22,453
-1,900
| -8% | -$437K |
|
69
Thermo Fisher Scientific
TMO
$183B
| $4.84M | 0.34% |
10,400
+1,750
| +20% | +$815K |
|
70
Medtronic
MDT
$118B
| $4.51M | 0.32% |
38,501
-3,250
| -8% | -$381K |
|
71
Vertex Pharmaceuticals
VRTX
$102B
| $4M | 0.28% |
16,921
+7,050
| +71% | +$1.67M |
|
72
FibroGen
FGEN
$48.4M
| $3.86M | 0.27% |
4,160
| – | – |
|
73
CRISPR Therapeutics
CRSP
$4.82B
| $3.82M | 0.27% |
+24,970
| New | +$3.82M |
|
74
Apellis Pharmaceuticals
APLS
$3.51B
| $3.72M | 0.26% |
+65,000
| New | +$3.72M |
|
75
Merck
MRK
$210B
| $3.64M | 0.26% |
46,636
-6,288
| -12% | -$491K |
|